[Enzyme therapy in treatment of mastopathy. A randomized double-blind clinical study].
In this randomized double-blind clinical study the efficacy of an enzyme preparation (Wobenzym) was compared with hormone therapy (Lynestrenol) in 29 women with mastopathy. There was a significantly greater decrease in number of hardenings of the mammary gland after 2 months of enzyme therapy than Lynestrenol therapy: improvement in the former group was 100%, in the latter group 78.6%. No significant difference was observed regarding the numbers of lumps, or number and size of cysts, sensitivity to touch, feeling of tension, spontaneous pain, and pain on pressure. The efficacy of both medicines is valued as good. Wobenzym therapy was tolerated very well. No side effects appeared at all. Enzyme therapy is an alternative, low-risk therapy for the management of mastopathy, which does not interfere with the already upset hormonal balance of the patients.
Rammer
E
E
Abteilung für Gynäkologic und Geburtshilfe, Allgemeines öffentliches Krankenhaus Horn.
Friedrich
F
F
D000328:Adult; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D004338:Drug Combinations; D005260:Female; D005348:Fibrocystic Breast Disease / Q000188:drug therapy*; D006801:Humans; D006867:Hydrolases / Q000009:adverse effects / Q000627:therapeutic use*; D008234:Lynestrenol / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D045167:Progesterone Congeners / Q000009:adverse effects / Q000627:therapeutic use*; D012431:Rutin / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
D004338:Drug Combinations; D045167:Progesterone Congeners; D012431:Rutin; C023295:Wobenzym; D006867:Hydrolases; D008234:Lynestrenol
Enzymtherapie zur Behandlung der Mastopathie. Eine randomisierte doppelblinde klinische Studie.